Last reviewed · How we verify

Preemptive Dexmedetomidine injection

China International Neuroscience Institution · FDA-approved active Small molecule

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Preoperative sedation and anxiolysis, Perioperative analgesia and sedation, Reduction of anesthetic and opioid requirements during surgery.

At a glance

Generic namePreemptive Dexmedetomidine injection
Also known asPreemptive Dex
SponsorChina International Neuroscience Institution
Drug classAlpha-2 adrenergic receptor agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAnesthesia and Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. When used preemptively (before anesthesia or surgery), it reduces anxiety, decreases anesthetic requirements, and provides perioperative analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: